A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
← catalyst calendarSponsored by Genenta Science (industry) · GNTA — their whole pipeline →.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-05 | actual | When the study began enrolling |
| Primary completion | 2026-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-27 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma Multiforme
Intervention
- Drug: Temferon
Primary outcome
what the primary-completion date above is the date OFPublications
- PMID 42225991 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GNTA's whole pipeline · Catalyst calendar · Every registered study · What changed